In a patient with primary sclerosing cholangitis and inflammatory bowel disease who developed drug‑induced liver injury after receiving the recombinant zoster vaccine (Shingrix), should they avoid influenza and COVID‑19 vaccines, and what is the likelihood of a similar reaction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Vaccination Safety After Shingrix-Associated DILI in PSC-IBD Patients

A patient with PSC and IBD who developed DILI after Shingrix should NOT avoid influenza and COVID-19 vaccines, as these are mechanistically different vaccines with distinct safety profiles, and the benefits of protection against vaccine-preventable infections far outweigh theoretical cross-reactivity risks. The likelihood of a similar hepatotoxic reaction to flu or COVID vaccines is extremely low and should not preclude vaccination in this high-risk population.

Key Reasoning

Different Vaccine Platforms = Different Risk Profiles

Shingrix is a recombinant protein vaccine with AS01B adjuvant 1, while:

  • Influenza vaccines are inactivated or recombinant protein vaccines (different antigens, different/no adjuvant)
  • COVID-19 vaccines include mRNA, viral vector, or inactivated platforms 2

The adjuvant system in Shingrix (AS01B) is unique and likely contributed to the DILI reaction. This adjuvant is not present in flu or COVID vaccines, making cross-reactivity highly unlikely. The hepatotoxicity mechanism appears idiosyncratic rather than a class effect of all vaccines.

IBD Patients Should Receive All Inactivated Vaccines

International guidelines are unequivocal: patients with IBD should receive COVID-19 and influenza vaccines regardless of immunosuppressive therapy status 2. The Canadian Association of Gastroenterology and International Organization for IBD (IOIBD) specifically state that vaccination should not be deferred in IBD patients on any immune-modifying therapy 3, 2.

Risk-Benefit Analysis Strongly Favors Vaccination

Patients with PSC-IBD face:

  • Increased infection risk from immunosuppression
  • Higher morbidity/mortality from influenza and COVID-19
  • Complex immune dysregulation already present 4

Versus the risk of:

  • Extremely rare vaccine-associated liver injury with COVID vaccines 5, 6, 7, 8
  • No documented cases of flu vaccine causing DILI in this population
  • Even when COVID vaccine-associated liver injury occurs, most cases resolve with or without immunosuppression 6

Quantifying the Risk

COVID-19 Vaccine-Associated Liver Injury

  • Extremely rare - case reports only 5, 6, 7, 8
  • When it occurs, typically presents as autoimmune-like hepatitis (not the same pattern as Shingrix DILI) 6
  • Most cases respond to corticosteroids and resolve 6
  • One case series showed transient enzyme elevations that resolved without treatment 6

Influenza Vaccine

  • No established association with DILI in IBD or PSC populations
  • Decades of safety data in immunocompromised patients 3

Shingrix-Specific Considerations

The FDA label notes general adverse reactions (pain, fatigue, myalgia) but does not list hepatotoxicity as a recognized adverse event 1. Your patient's DILI was likely an idiosyncratic reaction, not a predictable class effect.

Clinical Approach

Proceed with flu and COVID vaccination using this algorithm:

  1. Monitor liver enzymes before vaccination - establish baseline
  2. Administer vaccine (do not withhold)
  3. Check liver enzymes 2-4 weeks post-vaccination if concerned
  4. Counsel patient about general vaccine side effects (fever, fatigue) but emphasize these are NOT liver injury

Important Caveats

  • If active hepatic decompensation or acute liver injury is present, defer vaccination until stabilized (this is standard practice, not specific to prior Shingrix reaction)
  • Document the Shingrix DILI clearly in the medical record to avoid future Shingrix doses
  • Consider spacing vaccines (give flu and COVID separately by 2-4 weeks) to isolate any potential reaction, though co-administration is generally safe

What to Avoid

  • Do NOT extrapolate the Shingrix reaction to all vaccines
  • Do NOT check anti-vaccine antibody titers routinely (not clinically actionable in this scenario)
  • Do NOT delay vaccination waiting for "perfect" liver function in a patient with chronic liver disease

Real-World Evidence

A 2026 study of RZV (Shingrix) in IBD patients showed no serious vaccine-related adverse events and no significant changes in disease activity 9. Importantly, this demonstrates that even the vaccine that caused your patient's DILI has an overall favorable safety profile in IBD, suggesting the reaction was truly idiosyncratic.

The bottom line: Cross-reactivity between Shingrix and other vaccines is biologically implausible, clinically undocumented, and should not prevent life-saving vaccination in a patient with PSC-IBD who faces substantial infection-related morbidity and mortality.

References

Related Questions

Does Shingrix (recombinant varicella‑zoster glycoprotein E vaccine) contain any components that are also present in seasonal influenza vaccines or COVID‑19 vaccines, given the patient experienced drug‑induced liver injury after Shingrix and is hesitant to receive another vaccine?
Is the AS01B adjuvant used in any other vaccines, and what other components of the recombinant zoster vaccine (Shingrix) could have caused the patient’s drug‑induced liver injury?
Are there any studies or guidelines regarding breakthrough herpes zoster in individuals who have received the recombinant zoster vaccine (Shingrix)?
Should a young adult who is seropositive for varicella from the chickenpox vaccine receive the recombinant zoster vaccine (Shingrix) if they have ulcerative colitis and are on immunosuppressive therapy?
If a patient receives the second dose of the shingles vaccine (Shingrix, recombinant zoster vaccine) on schedule, are they more likely to experience significant side effects than after the first dose?
Does glucose cross the blood-brain barrier?
What percentage of patients experience constipation while receiving tirzepatide?
Which of the following statements about psoriatic arthritis are correct?
What is the pathophysiology of cerebral ischemia?
What is the recommended management for polyarticular osteoarthritis?
Is there increased sympathetic tone in systemic lupus erythematosus?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.